3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Refractory Solid Tumors
1
Carcinoma, Transitional Cell
1
Interventions
Bevacizumab
11
atezolizumab
8
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Nivolumab
6
durvalumab
5
tremelimumab
3
lenvatinib
3
cabozantinib
3
Ipilimumab
3
ulixertinib
2
tislelizumab
2
relatlimab
2
donafenib
2
camrelizumab
2
apatinib
2
X-Rays
2
Surgical Procedures, Operative
2
Sorafenib
2
Oxaliplatin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
sonidegib
1
sofosbuvir-velpatasvir drug combination
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
eribulin
×
30 days
×
Clear all
No trials found.